𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Angiogenesis and vascular targeting in Ewing sarcoma : A review of preclinical and clinical data

✍ Scribed by Steven G. DuBois; Neyssa Marina; Julia Glade-Bender


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
165 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Synthetic siRNA targeting the breakpoint
✍ Iori Takigami; Takatoshi Ohno; Yukio Kitade; Akira Hara; Akihito Nagano; Gou Kaw πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 540 KB

## Abstract The __EWS__/__Fli‐1__ fusion gene, a product of the translocation t(11;22, q24;q12), is detected in 85% of Ewing sarcomas and primitive neuroectodermal tumors. It is thought to be a transcriptional activator that plays a significant role in tumorigenesis. In this study, we developed a n

Analysis of prognostic factors in ewing
✍ Carlos RodrΓ­guez-Galindo; Tiebin Liu; Matthew J. Krasin; Jianrong Wu; Catherine πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 146 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Advances in systemic and local therapies have improved outcomes for patients with the Ewing sarcoma family of tumors (ESFT). As new treatments are developed, a critical review of data from past treatment eras is needed to identify clinically relevant risk groups. ## MET

Role of a muscle target organ on the reg
✍ Manfred Frey; Rupert Koller; Christian Liegl; Wolfgang Happak; Helmut Gruber πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 934 KB

principal difference between experimental and clinical data. Nevertheless one of these multiple factors in complex neuromuscular reconstructions might clarify whether the rethe extensive surgical effort is worthwhile.

Clinical outcomes of molecularly confirm
✍ Dan G. Blazer III; Alexander J. Lazar; Yan Xing; Robert L. Askew; Barry W. Feig; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 405 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: The authors compared disease‐specific survival (DSS) in stage‐specific subgroups of patients with clear cell sarcoma, including those with lymph node metastases (N1M0) and those with distant metastases (N0M1). ## METHODS: Clinical data regarding soft tissue sarcoma pat